Bellevue Group AG Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bellevue Group AG purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 40,900 shares of the biotechnology company’s stock, valued at approximately $270,000.

A number of other large investors have also added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new position in shares of ADMA Biologics in the first quarter valued at $31,000. Simplicity Wealth LLC purchased a new position in shares of ADMA Biologics in the 1st quarter worth $68,000. Viewpoint Capital Management LLC increased its holdings in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after buying an additional 2,416 shares during the last quarter. AJOVista LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at about $77,000. Finally, Oxford Asset Management LLP bought a new position in shares of ADMA Biologics in the 4th quarter valued at about $83,000. Institutional investors own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Stock Down 6.0 %

NASDAQ ADMA traded down $0.79 on Monday, reaching $12.37. 2,885,171 shares of the stock traded hands, compared to its average volume of 2,878,996. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $14.03. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -618.50 and a beta of 0.54. The company has a fifty day moving average price of $11.20 and a 200-day moving average price of $7.87. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million during the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm’s quarterly revenue was up 43.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.03) earnings per share. As a group, research analysts forecast that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ADMA shares. HC Wainwright upped their price objective on ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $10.00 to $15.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Mizuho increased their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, Raymond James boosted their price objective on ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of “Buy” and a consensus price target of $12.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.